NASDAQ:GRI GRI Bio (GRI) Stock Price, News & Analysis $1.62 -0.12 (-6.90%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$1.62 0.00 (-0.06%) As of 07/13/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About GRI Bio Stock (NASDAQ:GRI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GRI Bio alerts:Sign Up Key Stats Today's Range$1.59▼$1.7250-Day Range$1.62▼$2.3652-Week Range$1.59▼$80.36Volume54,678 shsAverage Volume105,371 shsMarket Capitalization$2.87 millionP/E RatioN/ADividend YieldN/APrice Target$32.00Consensus RatingHold Company Overview GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. Read More GRI Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreGRI MarketRank™: GRI Bio scored higher than 71% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingGRI Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialGRI Bio has a consensus price target of $32.00, representing about 1,875.3% upside from its current price of $1.62.Amount of Analyst CoverageGRI Bio has only been the subject of 2 research reports in the past 90 days.Read more about GRI Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GRI Bio are expected to grow in the coming year, from ($4.77) to ($2.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GRI Bio is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GRI Bio is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGRI Bio has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GRI Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.11% of the float of GRI Bio has been sold short.Short Interest Ratio / Days to CoverGRI Bio has a short interest ratio ("days to cover") of 0.66, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GRI Bio has recently decreased by 14.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGRI Bio does not currently pay a dividend.Dividend GrowthGRI Bio does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentGRI Bio has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for GRI Bio this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for GRI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added GRI Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GRI Bio insiders have not sold or bought any company stock.Percentage Held by Insiders8.73% of the stock of GRI Bio is held by insiders.Percentage Held by Institutions33.95% of the stock of GRI Bio is held by institutions.Read more about GRI Bio's insider trading history. Receive GRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRI Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRI Stock News HeadlinesGRI Bio Inc.June 26, 2026 | marketwatch.comGRI Bio, Inc.: GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary FibrosisJune 18, 2026 | finanznachrichten.deForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI patent could trigger a wealth wave they're calling his biggest breakthrough yet. They're tracking a market pattern with a 100% historical track record of major gains, and they believe it's about to collide with this invention. The last time it triggered, investors had a chance to turn $10,000 into $350,000 in roughly 12 months. | Brownstone Research (Ad)GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary FibrosisJune 18, 2026 | globenewswire.comGRI Bio to Present at A.G.P.’s Annual Healthcare Company ShowcaseMay 18, 2026 | markets.businessinsider.comGRI Bio to Present at A.G.P.'s Annual Healthcare Company ShowcaseMay 18, 2026 | globenewswire.comGRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued ...May 14, 2026 | markets.businessinsider.comGRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating PipelineMay 14, 2026 | globenewswire.comSee More Headlines GRI Stock Analysis - Frequently Asked Questions How have GRI shares performed this year? GRI Bio's stock was trading at $6.9104 on January 1st, 2026. Since then, GRI shares have decreased by 76.6% and is now trading at $1.62. How were GRI Bio's earnings last quarter? GRI Bio, Inc. (NASDAQ:GRI) posted its quarterly earnings results on Wednesday, May, 13th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.61) by $0.01. When did GRI Bio's stock split? GRI Bio shares reverse split on the morning of Monday, January 26th 2026.The 1-28 reverse split was announced on Wednesday, January 21st 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 23rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did GRI Bio IPO? GRI Bio (GRI) raised $20 million in an initial public offering on Friday, February 5th 2021. The company issued 2,250,000 shares at $8.00-$10.00 per share. How do I buy shares of GRI Bio? Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GRI Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that GRI Bio investors own include SoFi Technologies (SOFI), NuCana (NCNA), Caribou Biosciences (CRBU), Cardio Diagnostics (CDIO), Intrusion (INTZ), Children's Place (PLCE). Company Calendar Last Earnings5/13/2026Today7/13/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 GRI's financial health is in the Red zone, according to TradeSmith. GRI has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRI Previous SymbolNASDAQ:VLON CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees1Year Founded2009Price Target and Rating Average Price Target for GRI Bio$32.00 High Price Target$32.00 Low Price Target$32.00 Potential Upside/Downside+1,875.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($74.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.96 million Net MarginsN/A Pretax MarginN/A Return on Equity-199.52% Return on Assets-143.23% Debt Debt-to-Equity RatioN/A Current Ratio14.20 Quick Ratio14.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.16 per share Price / Book0.39Miscellaneous Outstanding Shares1,770,000Free Float1,616,000Market Cap$2.87 million OptionableNot Optionable Beta-1.21 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:GRI) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
